Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could tiny lung valves revive heart and muscle strength in COPD?

NCT ID NCT05775588

Disease control Sponsor: China-Japan Friendship Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether implanting small valves in the airways—a procedure called lung volume reduction—can improve heart and skeletal muscle function in people with severe chronic obstructive pulmonary disease (COPD). Participants will undergo the procedure and be followed for a year with imaging, breathing tests, exercise assessments, and quality-of-life questionnaires. The goal is to see if reducing over-inflated lung tissue helps the heart pump better and strengthens muscles.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lung volume reduction surgery with endobronchial valve implantation
What this could lead to
If successful, this procedure could improve heart and muscle function, exercise tolerance, and quality of life in people with severe COPD.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. The procedure carries risks, and benefits may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Mar 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with Chronic Obstructive Pulmonary Disease * FEV1 ≤ 45% pred and FEV1/FVC\<70% * TLC\>100% pred and RV\>175% pred * CAT score≥18 * Emphysema damage\>50% * Complete interlobar fissure \>95% based on quantitative analysis of CT measurement * No smoking\>6 months * Sign the informed consent form Exclusion Criteria: * PaCO2\>8.0 kPa, or PaO2\<6.0 kPa * 6-minute walk test\<160m * Obvious chronic bronchitis, bronchiectasis or other infectious pulmonary diseases * More than 3 hospitalizations for pulmonary infection in the past 12 months before baseline assessment * Previous lobectomy, LVRS or lung transplantation * LVEF\<45% and or RVSP\>50mmHg * Anticoagulant therapy that cannot be stopped before surgery * Patients with obvious immune deficiency * Participated in other lung drug studies within the first 30 days of this study * Pulmonary nodules requiring intervention * Any disease or condition that interferes with the completion of the initial or subsequent assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, 100029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.